Travere Therapeutics (NASDAQ:TVTX) Insider Sells $199,200.00 in Stock

by · The Markets Daily

Travere Therapeutics, Inc. (NASDAQ:TVTX – Get Free Report) insider Peter Heerma sold 4,980 shares of the stock in a transaction that occurred on Wednesday, December 24th. The stock was sold at an average price of $40.00, for a total transaction of $199,200.00. Following the transaction, the insider owned 113,013 shares in the company, valued at approximately $4,520,520. The trade was a 4.22% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Peter Heerma also recently made the following trade(s):

  • On Friday, October 31st, Peter Heerma sold 5,591 shares of Travere Therapeutics stock. The shares were sold at an average price of $35.00, for a total transaction of $195,685.00.
  • On Tuesday, October 28th, Peter Heerma sold 2,662 shares of Travere Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $79,860.00.

Travere Therapeutics Price Performance

Travere Therapeutics stock opened at $38.21 on Thursday. The firm has a market cap of $3.42 billion, a PE ratio of -36.05 and a beta of 0.89. The company has a debt-to-equity ratio of 4.23, a current ratio of 2.75 and a quick ratio of 2.71. The stock’s fifty day moving average price is $34.77 and its two-hundred day moving average price is $24.86. Travere Therapeutics, Inc. has a one year low of $12.91 and a one year high of $42.13.

Travere Therapeutics (NASDAQ:TVTX – Get Free Report) last released its earnings results on Thursday, October 30th. The company reported $0.28 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.31) by $0.59. The company had revenue of $164.86 million for the quarter, compared to analyst estimates of $106.09 million. Travere Therapeutics had a negative return on equity of 178.68% and a negative net margin of 20.32%.Travere Therapeutics’s quarterly revenue was up 162.1% on a year-over-year basis. During the same period in the prior year, the firm posted ($0.70) EPS. As a group, research analysts expect that Travere Therapeutics, Inc. will post -1.4 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on the stock. HC Wainwright reiterated a “buy” rating and set a $47.00 price target on shares of Travere Therapeutics in a research report on Friday, November 28th. Zacks Research downgraded Travere Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, November 12th. Stifel Nicolaus boosted their price target on Travere Therapeutics from $20.00 to $25.00 and gave the stock a “hold” rating in a report on Friday, September 12th. Weiss Ratings restated a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, October 8th. Finally, Piper Sandler raised their price objective on Travere Therapeutics from $26.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday, November 4th. Thirteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $38.71.

View Our Latest Stock Report on TVTX

Institutional Investors Weigh In On Travere Therapeutics

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Raymond James Financial Inc. acquired a new stake in shares of Travere Therapeutics during the second quarter worth $33,000. First Horizon Corp bought a new position in shares of Travere Therapeutics in the 3rd quarter worth about $36,000. Headlands Technologies LLC acquired a new position in shares of Travere Therapeutics in the 2nd quarter valued at about $73,000. Atria Investments Inc bought a new position in shares of Travere Therapeutics during the 2nd quarter worth approximately $154,000. Finally, Gallagher Fiduciary Advisors LLC acquired a new stake in Travere Therapeutics in the second quarter worth $155,000.

Travere Therapeutics Company Profile

(Get Free Report)

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.

Read More